Rilonacept (Arcalyst ®) in the Treatment of Subacromial Bursitis
Status:
Completed
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
To date no trials have been performed looking at whether or not intra-bursal injection of an
IL-1 antagonist provides pain relief similar to that of a corticosteroid injection. The
subcutaneous injection of anakinra, an IL-1 receptor antagonist, in patients with shoulder
pain due to rotator cuff tendonitis and subacromial bursitis was efficacious in relieving
pain but this information was presented as a case series in a letter to the editor format, so
the validity of these results would require additional testing [Omoigui S, et al. 2004].
Based mainly on the data from the intra-articular administration of anakinra, there have not
been any adverse trends in outcomes or safety to suggest that intra-bursal injection of
rilonacept will carry an increase risk of adverse events. The purpose of this trial is to
compare the improvement in pain and function of patients with clinical symptoms and signs of
subacromial bursitis of rilonacept vs. corticosteroid injection (standard of care).